In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology

To the editor: Controlled studies in polycythemia vera (PV) have demonstrated the value of aggressive phlebotomy, aspirin, and cytoreductive therapy in preventing thrombotic complications.[1][1][⇓][2]-[3][3] In the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP)